Healthcare — Institutional Ownership & Hedge Fund Activity
Track hedge fund buying and selling activity in Healthcare stocks based on SEC 13F filings for Q3 2026.
Most Bought Healthcare Stocks
| # | Stock | Company | Funds Buying | Net $ Change |
|---|
| 1 | LLY | Eli Lilly and Company | 67 | +$124.8M |
| 2 | JNJ | Johnson & Johnson | 53 | +$535.2M |
| 3 | ABBV | AbbVie Inc. | 51 | +$38.0M |
| 4 | MDT | Medtronic Plc | 47 | +$335.1B |
| 5 | MRK | Merck & Co., Inc. | 42 | +$107.0M |
| 6 | PFE | Pfizer Inc. | 40 | +$10.3B |
| 7 | ABT | Abbott Laboratories | 39 | $-278.3B |
| 8 | AMGN | Amgen Inc. | 38 | +$144.4M |
| 9 | UNH | UnitedHealth Group Incorporated | 38 | +$125.3M |
| 10 | SYK | Stryker Corporation | 37 | +$160.1M |
| 11 | ISRG | Intuitive Surgical, Inc. | 36 | $-60.7M |
| 12 | TMO | Thermo Fisher Scientific Inc. | 35 | +$496.6M |
| 13 | BMY | Bristol-Myers Squibb Company | 33 | +$105.6B |
| 14 | GILD | Gilead Sciences, Inc. | 33 | +$53.3M |
| 15 | DHR | Danaher Corporation | 30 | $-578.3M |
| 16 | VRTX | Vertex Pharmaceuticals Incorporated | 26 | +$55.5M |
| 17 | CNC | Centene Corp. | 25 | +$13.4B |
| 18 | CVS | CVS Health Corp. | 25 | +$1.1T |
| 19 | EW | Edwards Lifesciences Corporation | 25 | $-70.4B |
| 20 | MCK | McKesson Corporation | 25 | +$311.4M |
Most Sold Healthcare Stocks
| # | Stock | Company | Funds Selling | Net $ Change |
|---|
| 1 | JNJ | Johnson & Johnson | 66 | +$535.2M |
| 2 | MRK | Merck & Co., Inc. | 63 | +$107.0M |
| 3 | ABBV | AbbVie Inc. | 57 | +$38.0M |
| 4 | ABT | Abbott Laboratories | 50 | $-278.3B |
| 5 | PFE | Pfizer Inc. | 49 | +$10.3B |
| 6 | LLY | Eli Lilly and Company | 44 | +$124.8M |
| 7 | AMGN | Amgen Inc. | 40 | +$144.4M |
| 8 | TMO | Thermo Fisher Scientific Inc. | 39 | +$496.6M |
| 9 | BMY | Bristol-Myers Squibb Company | 35 | +$105.6B |
| 10 | SYK | Stryker Corporation | 35 | +$160.1M |
| 11 | UNH | UnitedHealth Group Incorporated | 34 | +$125.3M |
| 12 | DHR | Danaher Corporation | 32 | $-578.3M |
| 13 | CVS | CVS Health Corp. | 30 | +$1.1T |
| 14 | GILD | Gilead Sciences, Inc. | 30 | +$53.3M |
| 15 | CI | Cigna Corporation | 29 | $-17.7M |
| 16 | MCK | McKesson Corporation | 29 | +$311.4M |
| 17 | ISRG | Intuitive Surgical, Inc. | 28 | $-60.7M |
| 18 | ZTS | Zoetis Inc. | 27 | $-62.0B |
| 19 | BDX | Becton, Dickinson and Company | 26 | +$126.4M |
| 20 | IDXX | IDEXX Laboratories, Inc. | 26 | $-18.9M |
Most Widely Held Healthcare Stocks
| # | Stock | Company | Institutional Holders | Total Value |
|---|
| 1 | JNJ | Johnson & Johnson | 302 | $14.0B |
| 2 | LLY | Eli Lilly and Company | 281 | $13.1B |
| 3 | ABBV | AbbVie Inc. | 275 | $6.2B |
| 4 | MRK | Merck & Co., Inc. | 255 | $5.9B |
| 5 | AMGN | Amgen Inc. | 225 | $3.8B |
| 6 | ABT | Abbott Laboratories | 213 | $2.6T |
| 7 | PFE | Pfizer Inc. | 205 | $2.1T |
| 8 | UNH | UnitedHealth Group Incorporated | 193 | $5.3B |
| 9 | TMO | Thermo Fisher Scientific Inc. | 185 | $4.7B |
| 10 | BMY | Bristol-Myers Squibb Company | 169 | $2.7T |
| 11 | SYK | Stryker Corporation | 158 | $1.9B |
| 12 | MDT | Medtronic Plc | 153 | $3.8T |
| 13 | GILD | Gilead Sciences, Inc. | 152 | $2.9B |
| 14 | DHR | Danaher Corporation | 144 | $2.3B |
| 15 | ISRG | Intuitive Surgical, Inc. | 143 | $3.9B |
| 16 | MCK | McKesson Corporation | 128 | $2.3B |
| 17 | CVS | CVS Health Corp. | 126 | $3.1T |
| 18 | VRTX | Vertex Pharmaceuticals Incorporated | 112 | $2.6B |
| 19 | ELV | Elevance Health Inc. | 99 | $1.7B |
| 20 | CI | Cigna Corporation | 98 | $1.1B |
Data sourced from SEC 13F filings for Q3 2026. Filings are delayed up to 45 days after quarter end.